Optimization Of Lead Small Molecule Inhibitors Of Taspase1 For Cancer Therapeutics

Tech ID: 34432 / UC Case 2019-022-0

TECHNOLOGY DESCRIPTION

Researchers at UCSF have developed potent and selective small molecule inhibitors of Taspase1, a unique protease that plays a critical role in cancer cell proliferation and survival. Taspase1 is overexpressed in various cancers, including glioblastoma and melanoma, and its inhibition has shown promising results in disrupting tumor growth in preclinical models. This innovative therapeutic strategy is currently at the proof-of-concept stage, with compounds demonstrating strong enzyme inhibition and activity in cancer cell lines.

STAGE OF DEVELOPMENT

proof-of-concept

RELATED MATERIALS

PATENT STATUS

Patent Pending

CONTACT

Catherine Smith

Catherine.Smith2@ucsf.edu

tel: 510-646-0631.

OTHER INFORMATION

CATEGORIZED AS

- Medical
  - Disease: Cancer
  - New Chemical Entities, Drug Leads

RELATED CASES

2019-022-0

ADDRESS

UCSF

Innovation Ventures

600 16th St, Genentech Hall, S-272,

San Francisco,CA 94158

CONTACT

Tel:

innovation@ucsf.edu

https://innovation.ucsf.edu

Fax: